{"id":"https://openalex.org/W3083190503","doi":"https://doi.org/10.1158/1538-7445.am2020-4443","title":"Abstract 4443: Inhibition of PGE2/EP4 pathway by ONO-4578/BMS-986310, a novel EP4 antagonist, promotes T cell activation and myeloid cell differentiation to dendritic cells","display_name":"Abstract 4443: Inhibition of PGE2/EP4 pathway by ONO-4578/BMS-986310, a novel EP4 antagonist, promotes T cell activation and myeloid cell differentiation to dendritic cells","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083190503","doi":"https://doi.org/10.1158/1538-7445.am2020-4443","mag":"3083190503"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-4443","doi":"https://doi.org/10.1158/1538-7445.am2020-4443","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-4443","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058910159","display_name":"Tohru Kotani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tohru Kotani","raw_affiliation_strings":["1ONO Pharmaceutical Co., Ltd., Osaka, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1ONO Pharmaceutical Co., Ltd., Osaka, Japan;","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036043164","display_name":"Hirotsugu Takano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hirotsugu Takano","raw_affiliation_strings":["1ONO Pharmaceutical Co., Ltd., Osaka, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1ONO Pharmaceutical Co., Ltd., Osaka, Japan;","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081776349","display_name":"Tomoko Yoshida","orcid":"https://orcid.org/0000-0003-3340-7096","observed_orcids":["https://orcid.org/0000-0003-3340-7096"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoko Yoshida","raw_affiliation_strings":["1ONO Pharmaceutical Co., Ltd., Osaka, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1ONO Pharmaceutical Co., Ltd., Osaka, Japan;","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042575595","display_name":"Ryota Hamasaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryota Hamasaki","raw_affiliation_strings":["1ONO Pharmaceutical Co., Ltd., Osaka, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1ONO Pharmaceutical Co., Ltd., Osaka, Japan;","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022169733","display_name":"Gary Kohanbash","orcid":"https://orcid.org/0000-0002-3953-8022","observed_orcids":["https://orcid.org/0000-0002-3953-8022"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary Kohanbash","raw_affiliation_strings":["2University of Pittsburgh, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Pittsburgh, Pittsburgh, PA;","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112748334","display_name":"Kazuhiko Takeda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuhiko Takeda","raw_affiliation_strings":["1ONO Pharmaceutical Co., Ltd., Osaka, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1ONO Pharmaceutical Co., Ltd., Osaka, Japan;","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058793243","display_name":"Hideho Okada","orcid":"https://orcid.org/0000-0003-0076-9920","observed_orcids":["https://orcid.org/0000-0003-0076-9920"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hideho Okada","raw_affiliation_strings":["3University of California San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3University of California San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"4443","last_page":"4443"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11313","display_name":"Immune cells in cancer","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ep4-antagonist","display_name":"EP4 antagonist","score":0.8790000081062317},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.8339999914169312},{"id":"https://openalex.org/keywords/dendritic-cell-differentiation","display_name":"dendritic cell differentiation","score":0.9779999852180481},{"id":"https://openalex.org/keywords/myeloid-cells","display_name":"myeloid cells","score":0.8190000057220459},{"id":"https://openalex.org/keywords/immunosuppressive-tumor-microenvironment","display_name":"immunosuppressive tumor microenvironment","score":0.8870000243186951},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.8230000138282776},{"id":"https://openalex.org/keywords/m2-macrophages","display_name":"M2 macrophages","score":0.9070000052452087},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/glioma","display_name":"glioma","score":0.8550000190734863},{"id":"https://openalex.org/keywords/ct26-cells","display_name":"CT26 cells","score":0.5899999737739563}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6182183027267456},{"id":"https://openalex.org/C178592051","wikidata":"https://www.wikidata.org/wiki/Q28208812","display_name":"Prostaglandin E2 receptor","level":4,"score":0.6073470711708069},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.5239508152008057},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.40359142422676086},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3802102208137512},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36596590280532837},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3558461666107178},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2042059600353241},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.10440406203269958}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-4443","doi":"https://doi.org/10.1158/1538-7445.am2020-4443","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-4443","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3088028120","https://openalex.org/W2185199635","https://openalex.org/W4389109455","https://openalex.org/W4313200212","https://openalex.org/W2767570165","https://openalex.org/W2727513755","https://openalex.org/W3137014047","https://openalex.org/W7111276437","https://openalex.org/W4362541359","https://openalex.org/W4254454265"],"abstract_inverted_index":{"Abstract":[0],"Prostaglandin":[1],"E2":[2],"(PGE2)":[3],"contributes":[4],"to":[5,270],"immunosuppression":[6],"in":[7,43,65,80,93,103,127,141,180,184,205,218,222,228],"the":[8,39,128,206,277,281],"tumor":[9,152],"microenvironment":[10],"through":[11],"one":[12],"or":[13],"more":[14],"of":[15,72,88,99,120,138,150,156,174,208,253,276,280],"its":[16],"receptors":[17,51],"(EP1-EP4),":[18],"especially":[19],"EP4":[20,50,260],"which":[21],"is":[22,31,101,113,212],"expressed":[23],"at":[24],"high":[25],"levels":[26],"on":[27],"myeloid":[28,267],"cells.":[29],"ONO-4578/BMS-986310":[30,57,85,100,115,135,175,197,211],"a":[32,172,258],"novel":[33,259],"EP4-selective":[34],"antagonist":[35],"that":[36,110,134,196],"potently":[37],"inhibits":[38,86],"PGE2-induced":[40],"cAMP":[41],"production":[42],"CHO":[44],"cells":[45,162,272],"expressing":[46],"mouse":[47],"and":[48,76,90,163,176,186,201,217,266,291],"human":[49],"with":[52,84,122,145,169,191,220,230],"single-digit":[53],"nM":[54],"IC50.":[55],"Furthermore,":[56],"shows":[58],"excellent":[59],"pharmacokinetic":[60],"properties":[61],"after":[62,167],"oral":[63],"dosing":[64],"mouse.":[66,95],"ONO-4578/":[67],"BMS-986310":[68],"reverses":[69],"PGE2-mediated":[70],"suppression":[71],"T":[73,158,263],"cell":[74,264,268],"activation":[75,265],"promotes":[77,198,262],"DC":[78],"differentiation":[79,269],"vitro.":[81],"Moreover,":[82],"treatment":[83,116,168,207],"growth":[87],"CT26":[89,107],"MC38":[91,142,151,187],"tumors":[92,108,143,233],"syngeneic":[94],"The":[96],"anti-tumor":[97,182,199],"effect":[98,112],"abrogated":[102],"immuno-deficient":[104],"mice":[105,121,189],"bearing":[106],"indicating":[109],"such":[111],"immune-mediated.":[114],"significantly":[117],"prolongs":[118],"survival":[119],"highly":[123],"aggressive":[124],"SB28":[125],"gliomas":[126],"brain.":[129],"Flow":[130],"cytometric":[131],"analysis":[132,149],"reveals":[133],"reduces":[136],"infiltration":[137],"M2":[139],"macrophages":[140],"compared":[144,190],"control":[146],"mice.":[147],"Microarray":[148],"tissues":[153],"demonstrates":[154],"up-regulation":[155],"cytotoxic":[157],"lymphocytes,":[159],"natural":[160],"killer":[161],"innate":[164],"immunity-related":[165],"genes":[166],"ONO-4578/BMS-986310.":[170],"Finally,":[171],"combination":[173,219],"anti-PD-1":[177,192],"antibody":[178],"results":[179],"enhanced":[181],"effects":[183],"GL261":[185],"tumor-bearing":[188],"monotherapy.Our":[193],"data":[194],"demonstrate":[195],"immunity":[200],"may":[202],"be":[203],"useful":[204],"cancer":[209],"patients.":[210],"being":[213],"evaluated":[214],"as":[215],"monotherapy":[216],"nivolumab":[221],"an":[223],"ongoing":[224],"Ph1/1b":[225],"clinical":[226],"trials":[227],"patients":[229],"advanced":[231],"solid":[232],"(NCT03155061,":[234],"NCT03661632).":[235],"Citation":[236],"Format:":[237],"Tohru":[238],"Kotani,":[239],"Hirotsugu":[240],"Takano,":[241],"Tomoko":[242],"Yoshida,":[243],"Ryota":[244],"Hamasaki,":[245],"Gary":[246],"Kohanbash,":[247],"Kazuhiko":[248],"Takeda,":[249],"Hideho":[250],"Okada.":[251],"Inhibition":[252],"PGE2/EP4":[254],"pathway":[255],"by":[256],"ONO-4578/BMS-986310,":[257],"antagonist,":[261],"dendritic":[271],"[abstract].":[273],"In:":[274],"Proceedings":[275],"Annual":[278],"Meeting":[279],"American":[282],"Association":[283],"for":[284],"Cancer":[285,297],"Research":[286],"2020;":[287],"2020":[288],"Apr":[289],"27-28":[290],"Jun":[292],"22-24.":[293],"Philadelphia":[294],"(PA):":[295],"AACR;":[296],"Res":[298],"2020;80(16":[299],"Suppl):Abstract":[300],"nr":[301],"4443.":[302]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-09-11T00:00:00"}